DE69939527D1 - Zielsuchende verbindungen für verschiedene organe und gewebe - Google Patents
Zielsuchende verbindungen für verschiedene organe und gewebeInfo
- Publication number
- DE69939527D1 DE69939527D1 DE69939527T DE69939527T DE69939527D1 DE 69939527 D1 DE69939527 D1 DE 69939527D1 DE 69939527 T DE69939527 T DE 69939527T DE 69939527 T DE69939527 T DE 69939527T DE 69939527 D1 DE69939527 D1 DE 69939527D1
- Authority
- DE
- Germany
- Prior art keywords
- mdp
- molecule
- targeting
- links
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/806—Virus-based particle with exterior chemical attachment
- Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/912—Cancer cell repair
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/042,107 US6232287B1 (en) | 1998-03-13 | 1998-03-13 | Molecules that home to various selected organs or tissues |
US09/258,754 US6174687B1 (en) | 1999-02-26 | 1999-02-26 | Methods of identifying lung homing molecules using membrane dipeptidase |
PCT/US1999/005284 WO1999046284A2 (en) | 1998-03-13 | 1999-03-10 | Molecules that home to various selected organs or tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69939527D1 true DE69939527D1 (de) | 2008-10-23 |
Family
ID=26718876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69939527T Expired - Lifetime DE69939527D1 (de) | 1998-03-13 | 1999-03-10 | Zielsuchende verbindungen für verschiedene organe und gewebe |
Country Status (10)
Country | Link |
---|---|
US (1) | US6784153B1 (de) |
EP (1) | EP1062232B1 (de) |
JP (2) | JP4603157B2 (de) |
AT (1) | ATE407943T1 (de) |
AU (1) | AU762991B2 (de) |
CA (1) | CA2323071C (de) |
DE (1) | DE69939527D1 (de) |
ES (1) | ES2313779T3 (de) |
HK (1) | HK1033466A1 (de) |
WO (1) | WO1999046284A2 (de) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1304085A3 (de) | 1994-09-16 | 2004-01-21 | Ethicon Endo-Surgery, Inc. | Aus biologisch abbaubarem Material hergestellte Gewebemarkierungsvorrichtung |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
WO2000042973A2 (en) * | 1999-01-22 | 2000-07-27 | The Burnham Institute | Homing pro-apoptotic conjugates and methods of using same |
WO2001044463A1 (en) * | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
AU2001229494A1 (en) * | 2000-01-21 | 2001-07-31 | The Burnham Institute | Chimeric prostate-homing peptides with pro-apoptotic activity |
JP2003522183A (ja) * | 2000-02-02 | 2003-07-22 | トランジェーヌ、ソシエテ、アノニム | ターゲッティングペプチド |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
CA2421271A1 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
US7666391B2 (en) | 2001-06-01 | 2010-02-23 | Burnham Institute For Medical Research | Breast homing peptides and methods of identifying same using aminopeptidase P |
US7262269B2 (en) * | 2001-10-26 | 2007-08-28 | The Regents Of University Of California | Method for screening combinational bead library; ligands for cancer cells |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
US9321992B2 (en) | 2002-06-14 | 2016-04-26 | Case Western Reserve University | Cell targeting methods and compositions |
US7488792B2 (en) | 2002-08-28 | 2009-02-10 | Burnham Institute For Medical Research | Collagen-binding molecules that selectively home to tumor vasculature and methods of using same |
US20060263336A1 (en) * | 2003-03-24 | 2006-11-23 | Caplan Arnold I | Cell targeting methods and compositions |
CN102138869B (zh) * | 2003-09-08 | 2013-05-01 | 纳幕尔杜邦公司 | 基于肽的用于毛发、皮肤和指甲的调理剂和着色剂 |
US7220405B2 (en) * | 2003-09-08 | 2007-05-22 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
US7723474B2 (en) | 2003-10-21 | 2010-05-25 | The Regents Of The University Of California | Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies |
US7598341B2 (en) | 2003-10-31 | 2009-10-06 | Burnham Institue For Medical Research | Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs |
ZA200603619B (en) | 2003-11-06 | 2008-10-29 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US7608579B2 (en) * | 2004-06-16 | 2009-10-27 | Pneumrx, Inc. | Lung volume reduction using glue compositions |
US20050281798A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting sites of damaged lung tissue using composition |
US20050281799A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting damaged lung tissue using compositions |
US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
US20050281740A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
US20050281739A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue using compositions |
US7553810B2 (en) * | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
WO2006014567A2 (en) | 2004-07-08 | 2006-02-09 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
ATE538806T1 (de) * | 2004-09-07 | 2012-01-15 | Burnham Inst | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
JP5205275B2 (ja) * | 2005-12-21 | 2013-06-05 | セントクローネ インターナショナル エービー | 散在性ガンの治療法 |
WO2008036763A2 (en) * | 2006-09-20 | 2008-03-27 | Pneumrx, Inc. | Tissue adhesive compositions and methods thereof |
AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
SG10201600791TA (en) | 2010-06-08 | 2016-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
RS54446B1 (en) | 2011-10-14 | 2016-06-30 | Medimmune Limited | PIROLOBENZIDIAZEPINE AND ITS CONJUGATES |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
RS56520B1 (sr) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Pirolobenzodiazepin-anti-cd22 konjugati antitela |
EP2906296B1 (de) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
PL2906253T3 (pl) | 2012-10-12 | 2019-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-psma |
JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドMedImmune Limited | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
CN110452242A (zh) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
EA027910B1 (ru) | 2013-03-13 | 2017-09-29 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP3054985B1 (de) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
EP3054983B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
JP5885213B2 (ja) * | 2013-11-27 | 2016-03-15 | 東ソー有機化学株式会社 | 不飽和アルキルハライド類の製造方法 |
CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
KR20170042495A (ko) | 2013-12-16 | 2017-04-19 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
CA2959726A1 (en) | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック, インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
AU2015314826A1 (en) | 2014-09-12 | 2017-03-02 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
US10493127B2 (en) * | 2015-08-11 | 2019-12-03 | Arch Biopartners, Inc. | DPEP-1 binding compositions and methods of use |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP4273551A3 (de) | 2016-03-25 | 2024-01-17 | F. Hoffmann-La Roche AG | Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
EP3465221B1 (de) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten |
JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | シルベストロール抗体-薬物コンジュゲート及び使用方法 |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
EP3522933B1 (de) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Verfahren zur herstellung von antikörperarzneimittelkonjugaten |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
JP6671555B2 (ja) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
AU2018255876B2 (en) | 2017-04-18 | 2020-04-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US20200129637A1 (en) | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US20200216463A1 (en) | 2017-09-20 | 2020-07-09 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
CN113056287A (zh) | 2018-10-24 | 2021-06-29 | 豪夫迈·罗氏有限公司 | 缀合的化学降解诱导剂及使用方法 |
EP3894427A1 (de) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616038A (en) | 1978-07-24 | 1986-10-07 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
US4406902A (en) | 1980-09-17 | 1983-09-27 | Merck & Co., Inc. | Dipeptidase inhibitors |
US5061730A (en) | 1987-01-26 | 1991-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid derivatives |
US5145990A (en) | 1988-10-28 | 1992-09-08 | Merck & Co., Inc. | Phosphorous containing dhp enzyme inhibitors |
EP0876611A1 (de) * | 1995-09-11 | 1998-11-11 | La Jolla Cancer Research Foundation | Moleküle die sich in ausgewählten organen oder geweben in-vivo einfinden und verfahren zu ihrer identifizierung |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
GB9601640D0 (en) * | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
DE69734887T2 (de) * | 1996-09-10 | 2006-08-24 | The Burnham Institute, La Jolla | Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung |
CA2421271A1 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
-
1999
- 1999-03-10 WO PCT/US1999/005284 patent/WO1999046284A2/en active IP Right Grant
- 1999-03-10 EP EP99912400A patent/EP1062232B1/de not_active Expired - Lifetime
- 1999-03-10 AT AT99912400T patent/ATE407943T1/de not_active IP Right Cessation
- 1999-03-10 JP JP2000535660A patent/JP4603157B2/ja not_active Expired - Fee Related
- 1999-03-10 DE DE69939527T patent/DE69939527D1/de not_active Expired - Lifetime
- 1999-03-10 CA CA2323071A patent/CA2323071C/en not_active Expired - Fee Related
- 1999-03-10 ES ES99912400T patent/ES2313779T3/es not_active Expired - Lifetime
- 1999-03-10 AU AU30783/99A patent/AU762991B2/en not_active Ceased
-
2000
- 2000-09-29 US US09/676,475 patent/US6784153B1/en not_active Expired - Fee Related
-
2001
- 2001-06-11 HK HK01103991.2A patent/HK1033466A1/xx not_active IP Right Cessation
-
2009
- 2009-11-05 JP JP2009254478A patent/JP2010031038A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US6784153B1 (en) | 2004-08-31 |
JP4603157B2 (ja) | 2010-12-22 |
ES2313779T3 (es) | 2009-03-01 |
WO1999046284A9 (en) | 1999-11-18 |
AU3078399A (en) | 1999-09-27 |
WO1999046284A3 (en) | 2000-04-06 |
JP2002506079A (ja) | 2002-02-26 |
CA2323071A1 (en) | 1999-09-16 |
EP1062232A2 (de) | 2000-12-27 |
ATE407943T1 (de) | 2008-09-15 |
CA2323071C (en) | 2011-06-21 |
JP2010031038A (ja) | 2010-02-12 |
EP1062232B1 (de) | 2008-09-10 |
WO1999046284A2 (en) | 1999-09-16 |
AU762991B2 (en) | 2003-07-10 |
HK1033466A1 (en) | 2001-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69939527D1 (de) | Zielsuchende verbindungen für verschiedene organe und gewebe | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
HK1027820A1 (en) | Molecules that home to a selected organ or tissue in vivo | |
HK1058486A1 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
ATE369878T1 (de) | Träger-pharmaka-konjugate | |
DE69737867D1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
ATE465257T1 (de) | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen | |
CY1108127T1 (el) | Μεθοδοι για την προστασια αλλογενους μοσχευματος παγκρεατικων νησιδιων με χρηση διαλυτων μοριων μεταλλακτων ctla4 | |
BR0113849A (pt) | Filtro para fumaça de tabaco | |
AU1929199A (en) | Methods for the recovery and measurement of troponin complexes | |
BR0114199A (pt) | Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas | |
ATE483162T1 (de) | Trifunktionales reagenz zur verbindung von biomolekülen | |
BR9713581A (pt) | Método para aumentar a produção de alimentos marinhos no oceano. | |
WO2003107009A3 (en) | METHODS FOR IMPROVING A CHARACTERISTIC LINK OF A MOLECULE | |
DE60032784D1 (de) | Markerproteine für prostatakrebs | |
DE60323099D1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
WO2004108749A3 (en) | Binding peptides: methods for their generation and use | |
ATE417059T1 (de) | Verfahren zur herstellung hochreiner nicht toxischer toxinfragmente | |
ES2187834T3 (es) | Conjugados fluorescentes no agregados y su procedimiento de obtencion. | |
ATE419861T1 (de) | Peptide mit homing für lymphgefässtumor und ihre verwendung | |
DK1037642T3 (da) | Modificerede polysaccharider med ændret biologisk genkendelse | |
DE69905004D1 (de) | Dreidimensionales positioniersystem für endoluminal eingebrachtes material | |
ATE332916T1 (de) | Farbstoff-markiertes peptid und dessen verwendung zur diagnostik | |
DE60239938D1 (de) | Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates | |
DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |